X

ASCO 2021: Updates in NSCLC

ASCO 2021: Updates in NSCLC

Atezolizumab Reduces Risk of Disease Progression and Death in Patients With PD-L1–Expressing Early-Stage NSCLC

Atezolizumab given after CT to patients with resected stage II to IIIA NSCLC significantly improves DFS compared with best supportive care alone in patients whose tumors expressed PD-L1.

The ASCO Post
06/10/2021
NSCLC: Immune-Related AEs May Predict Survival Outcomes

Experiencing an immune-related adverse event during checkpoint inhibitor treatment may predict outcomes in patients with non-small cell lung cancer, exploratory analyses of phase 3 trials suggest.<

Medscape
06/07/2021
More Widespread Biomarker Testing for NSCLC in Oncology Practices and More Testing in Black Patients: An Urgent Priority

Even though next-generation sequencing is recommended for biomarker testing for patients with NSCLC, the uptake among community oncology practices is suboptimal, and the uptake is even lower among

The ASCO Post
06/08/2021

Radiotherapy and Surgery Produce Comparable Outcomes in Operable Stage IA Non-Small Cell Lung Cancer

Long-term results from the STARS trial indicate that SABR is not inferior to VATS with mediastinal lymph node dissection in patients with operable stage IA non-small cell lung cancer.

Cancer Therapy Advisor
06/07/2021
Sotorasib for KRAS G12C–Mutated NSCLC: Overall Survival and Exploratory Subgroup Analyses

Results show treatment with the KRAS G12C inhibitor sotorasib achieve a 37.1% ORR and a median overall survival of 12.5 months in previously treated patients with KRAS G12C–mutated NSCLC.<

The ASCO Post
06/05/2021
Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC

New data from Daiichi Sankyo on patritumab deruxtecan (HER3-DXd), a HER3 directed antibody drug conjugate (ADC), demonstrated clinically meaningful and durable tumor response in locally advanced or

06/04/2021
Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer

RARITAN, N.J., May 19, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib.

05/19/2021
Immunotherapy Delays Disease Recurrence in Patients With Early-Stage, Resected Non-Small Cell Lung Cancer

ALEXANDRIA, Va. – Treatment with the immunotherapy atezolizumab (Tecentriq) extended disease-free survival in patients with resected, early-stage non-small cell lung cancer, particularly those positive for the immune checkpoint protein PD-L1, according to new research to be presented at the 2021 American Society of Clinical Oncology Annual Meeting. The findings open the door to delaying recurrence even longer for patients with early-stage disease.

05/19/2021
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

This publication provides evidence-based recommendations updating the ASCO guideline on systemic therapy for patients with stage IV NSCLC with driver alterations.

Journal of Clinical Oncology

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834